Jushi (OTCMKTS:JUSHF – Get Free Report) and iRadimed (NASDAQ:IRMD – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, earnings, risk, analyst recommendations, dividends and valuation.
Analyst Ratings
This is a breakdown of recent ratings and target prices for Jushi and iRadimed, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Jushi | 0 | 0 | 1 | 0 | 3.00 |
| iRadimed | 0 | 1 | 3 | 1 | 3.00 |
iRadimed has a consensus price target of $120.00, suggesting a potential upside of 45.03%. Given iRadimed’s higher possible upside, analysts clearly believe iRadimed is more favorable than Jushi.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Jushi | $262.91 million | 0.32 | -$68.59 million | ($0.34) | -1.22 |
| iRadimed | $83.81 million | 12.63 | $22.48 million | $1.79 | 46.22 |
iRadimed has lower revenue, but higher earnings than Jushi. Jushi is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Jushi and iRadimed’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Jushi | -24.44% | N/A | -15.46% |
| iRadimed | 26.70% | 23.45% | 20.36% |
Institutional & Insider Ownership
21.7% of Jushi shares are held by institutional investors. Comparatively, 92.3% of iRadimed shares are held by institutional investors. 23.1% of Jushi shares are held by insiders. Comparatively, 34.6% of iRadimed shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Risk & Volatility
Jushi has a beta of -0.63, indicating that its stock price is 163% less volatile than the S&P 500. Comparatively, iRadimed has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500.
Summary
iRadimed beats Jushi on 13 of the 14 factors compared between the two stocks.
About Jushi
Jushi Holdings Inc., a vertically integrated cannabis company, engages in the cultivation, processing, retail, and distribution of cannabis for medical and adult-use markets. The company offers flower, extracts, concentrates, edibles, oil, pre-rolls, tinctures, capsules, softgels, cannabis-infused gummies and ultra-premium chocolate, and topicals products, as well as vaporization devices and cartridges under The Bank, The Lab, Nira+ Medicinals, Sèchè, Tasteology, and Hijinks brands. It is also involved in the bulk wholesale of refined cannabinoids and terpenes. In addition, the company operates medical cannabis dispensaries under the BEYOND/HELLO, Nature’s Remedy, and NuLeaf brands. It markets its products to local dispensaries and large multi-state operators. The company is headquartered in Boca Raton, Florida.
About iRadimed
IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.
Receive News & Ratings for Jushi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jushi and related companies with MarketBeat.com's FREE daily email newsletter.
